Innovative Pharmaceutical Biotech Limited ("IPB") has two primary segments of business: the research and development of pharmaceutical products and trading of beauty equipment and products. Currently, IPB is focused on developing an insulin product that could be administered orally. The company is keen to expand its research and development segment by acquiring additional pharmaceutical products with commercial viability.
IPB was formerly known as United Gene High-Tech Group Limited and focused on genetic testing, healthcare management and the distribution of bio-industrial products.
The shares of IPB are listed on the Main Board of the Hong Kong Stock Exchange under the code 399.
updated 26th January, 2016
| © Copyright 1996-2023 irasia.com Ltd. All rights reserved. |
|
DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any
information provided on this website. Under no circumstances shall irasia.com Ltd be liable
for damages resulting from the use of the information provided on this website.
TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website. |